Qube Research & Technologies (QRT)’s Aldeyra Therapeutics ALDX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4M	Buy	1,128,803 +1,041,725	+1,196%	+$1.79M	﹤0.01%	2042
2026 Q1	$147K	Buy	87,078 +2,150	+3%	+$9.42K	﹤0.01%	3011
2025 Q4	$440K	Buy	+84,928	New	+$436K	﹤0.01%	2840
2024 Q1	–	Sell	-15,629	Closed	-$54.9K	–	4429
2023 Q4	$54.9K	Buy	+15,629	New	+$48.2K	﹤0.01%	3287
2023 Q2	–	Sell	-78,556	Closed	-$780K	–	2355
2023 Q1	$780K	Buy	78,556 +21,737	+38%	+$154K	﹤0.01%	1392
2022 Q4	$395K	Buy	56,819 +21,091	+59%	+$121K	﹤0.01%	1560
2022 Q3	$191K	Buy	35,728 +16,313	+84%	+$97.9K	﹤0.01%	1785
2022 Q2	$77K	Buy	+19,415	New	+$66.8K	﹤0.01%	2023
2021 Q4	–	Sell	-43,459	Closed	-$382K	–	2488
2021 Q3	$382K	Sell	43,459 -5,039	-10%	-$46.2K	﹤0.01%	1365
2021 Q2	$549K	Sell	48,498 -9,004	-16%	-$108K	0.01%	1246
2021 Q1	$683K	Sell	57,502 -94,687	-62%	-$1.09M	0.01%	1009
2020 Q4	$1.04M	Buy	152,189 +108,303	+247%	+$760K	0.01%	860
2020 Q3	$325K	Buy	43,886 +23,256	+113%	+$150K	﹤0.01%	1205
2020 Q2	$86K	Buy	+20,630	New	+$75.4K	﹤0.01%	1535

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ALDX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Aldeyra Therapeutics (ALDX) stake by 1,196% in Q2 2026, buying an estimated $1.79M and bringing the position to 1,128,803 shares worth $2.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Qube Research & Technologies (QRT) first reported a position in ALDX in Q2 2020 and has held it in 14 quarters since. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Qube Research & Technologies (QRT) held 1,128,803 shares of Aldeyra Therapeutics worth $2.4M as of Q2 2026.
Qube Research & Technologies (QRT) bought 1,041,725 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.79M.
Aldeyra Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2042 holding.
Qube Research & Technologies (QRT) first reported a position in Aldeyra Therapeutics in Q2 2020 and has held it in 14 quarters since.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.